皓元医药(688131) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥504,874,103.59, representing a year-on-year increase of 20.68%[6] - The net profit attributable to shareholders decreased by 63.76% to ¥16,757,351.46, while the net profit after deducting non-recurring gains and losses fell by 66.82% to ¥13,922,308.47[6] - Basic and diluted earnings per share were both ¥0.11, down 64.52% compared to the same period last year[6] - Total operating revenue for Q1 2024 reached ¥504,874,103.59, a 20.7% increase from ¥418,365,040.62 in Q1 2023[27] - Net profit for Q1 2024 was ¥16,536,169.84, a decrease of 64.1% compared to ¥46,068,348.53 in Q1 2023[28] - The total comprehensive income for Q1 2024 was CNY 16,883,201.98, compared to CNY 46,325,683.35 in the same period last year, indicating a substantial drop[29] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.11, down from CNY 0.31 in Q1 2023, showing a decrease of approximately 64.52%[29] Assets and Liabilities - Total assets increased by 3.08% to ¥4,321,442,734.99 compared to the end of the previous year[6] - Cash and cash equivalents decreased to ¥445,315,659.88 from ¥483,611,131.37 in the previous quarter[23] - Total assets increased to ¥4,321,442,734.99 from ¥4,192,207,930.25 in the previous quarter, representing a growth of 3.1%[24] - Total liabilities rose to ¥1,758,122,155.73 from ¥1,665,929,876.55 in the previous quarter, indicating an increase of 5.5%[25] - The company's inventory stood at ¥1,159,862,781.66, slightly up from ¥1,145,471,760.05 in the previous quarter[23] - Long-term equity investments decreased to ¥60,950,420.41 from ¥63,531,275.19 in the previous quarter, a decline of 4.1%[23] Cash Flow - The company reported a net cash flow from operating activities of ¥28,325,486.01, which is not applicable for year-on-year comparison[6] - Cash inflows from operating activities totaled CNY 474,799,584.50 in Q1 2024, an increase of 26.96% from CNY 373,898,358.75 in Q1 2023[31] - The net cash flow from operating activities improved to CNY 28,325,486.01 in Q1 2024, compared to a net outflow of CNY -147,839,554.95 in Q1 2023[31] - The company experienced a net cash outflow from investing activities of CNY -119,512,265.14 in Q1 2024, a slight improvement from CNY -165,815,091.20 in Q1 2023[32] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 443,831,829.96, up from CNY 300,142,110.84 at the end of Q1 2023[32] - The company reported a significant increase in cash received from sales of goods and services, amounting to CNY 459,234,993.50 in Q1 2024, compared to CNY 366,230,295.47 in Q1 2023, marking a growth of 25.41%[31] - The company’s total cash outflow from operating activities was CNY 446,474,098.49 in Q1 2024, down from CNY 521,737,913.70 in Q1 2023, indicating improved cash management[31] Research and Development - Research and development expenses totaled ¥53,593,858.98, accounting for 10.62% of operating revenue, a decrease of 1.46 percentage points year-on-year[6] - Research and development expenses for Q1 2024 amounted to ¥53,593,858.98, compared to ¥50,524,023.51 in Q1 2023, reflecting a 4.1% increase[28] Shareholder Information - The company completed the employee stock ownership plan by purchasing a total of 4,066,437 shares, representing 2.70% of the current total share capital, at an average price of 36.88 RMB per share, totaling 149.9754 million RMB[19] - The employee stock ownership plan was approved on February 19, 2024, allowing for a maximum of 449,640 shares, which is 2.99% of the total share capital, with participation limited to 60 employees[18] - The company reported that the top 10 shareholders include significant entities such as Junxin (Shanghai) Equity Investment Fund Management Co., Ltd. holding 10,744,524 shares, and Hong Kong Central Clearing Limited holding 6,239,974 shares[15] - The total number of shares held by the top 10 unrestricted shareholders is significant, with the largest shareholder holding over 10 million shares[15] - The company’s stock purchase for the employee stock ownership plan was executed through the secondary market, including block trades and centralized bidding[18] - The company’s stock will be locked for 12 months from March 22, 2024, to March 21, 2025, as part of the employee stock ownership plan[19] - The company’s financial report includes a detailed list of major shareholders and their respective holdings, emphasizing the concentration of ownership among a few key investors[15] Operational Insights - The decline in net profit was attributed to a slowdown in investment in the pharmaceutical industry, increased competition, and higher operational costs due to the initial production phase of the Anshan factory[10] - The company has strengthened its sales team, resulting in increased sales expenses compared to the same period last year[10] - Non-recurring gains and losses amounted to ¥2,835,042.99 after tax and minority interest adjustments[10] - The company has not reported any changes in the number of shares lent or returned through the securities lending program compared to the previous period[17] - The company has not disclosed any significant operational changes or new strategies in the current report[18] - Total operating costs for Q1 2024 were ¥465,236,626.83, up 31.2% from ¥354,607,032.39 in Q1 2023[27]